DGAP-News: curasan signs exclusive Cooperation for Hemostatic Product stypro(R) in Germany

curasan signs exclusive Cooperation for Hemostatic Product stypro^(R) in Germany

- Exclusive Distribution Agreement for Hemostatic Sponge stypro^(R)

- Extensive Access to German Hospital Market

Kleinostheim, 26 June 2018 - curasan AG, Germany, a leading specialist for medical products in the field of orthobiologics, has signed an exclusive distribution agreement with P.J. Dahlhausen & Co. GmbH.

Starting beginning of July the company with headquarters in Cologne, Germany, is going to include curasan's hemostatic product stypro^(R) in their sales portfolio and, as a first step, place it on the German market.

"This cooperation with Dahlhausen underlines our strategy to continuously shift local sales activities at the point of sales, especially in hospitals, to specialists on site", explains Michael Schlenk, CEO of curasan AG. "With Dahlhausen we found a partner who is exceptionally well established in the hospital market and who can ensure a high presence at our target groups with more than 40 people in his hospital sales force."

"As one of the leading full-range suppliers of clinical accessories for hospitals throughout Germany we are increasingly extending our product line also for the orthopedics and traumatology sector", says Ulrich Dahlhausen, General Manager of the family business. "Therefore, the hemostatic product stypro^(R) is an ideal supplement for our portfolio."

stypro^(R) is a highly porous sponge made of porcine gelatin which supports the blood clotting process in a physiological way.

As P.J. Dahlhausen & Co. GmbH is globally active, the two companies will consider at a later point if the cooperation can be extended to other markets as well.

Your contact at curasan AG:
Andrea Weidner
Head of Investor Relations & Corporate Communications
+49 6027 40 900-51
andrea.weidner@curasan.com

About curasan AG:
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan.
curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.

About P.J. Dahlhausen & Co. GmbH
The company founded in 1854 develops, manufactures and markets high quality medical products with more than 500 employees within the group exporting and importing on a global scale. The company has positioned itself as a partner along the entire supply and value chain. As Europe's largest full-range provider of clinical supplies, the range of products comprising more than 3,000 different quality products systematically answers every need in
anesthesiology, surgery and patient care. Besides their headquarters in Cologne, Dahlhausen maintains a newly built production and logistics center in Halberstadt, Sachsen-Anhalt, with constantly expanding warehouse and production facilities. At this site, the company is setting new standards for the assembly and availability of medical devices throughout Germany.